Cathie Wood
CMMB

Cathie Wood’s Chemomab Therapeutics CMMB Stock Holding History

Cathie Wood’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-198
Closed -$4K – 351
2022
Q1 		$4K Sell
198
-66,625
-100% -$1.31M ﹤0.01% 351
2021
Q4 		$1.84M Buy
66,823
+21,692
+48% +$770K 0.01% 246
2021
Q3 		$2M Buy
+45,131
New +$2.75M ﹤0.01% 252

Other funds holding CMMB

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cathie Wood's CMMB Position: Q2 2022 in Review

Cathie Wood sold out of Chemomab Therapeutics (CMMB) in Q2 2022, closing a stake of 198 shares — an estimated $4K sold.

Cathie Wood first reported a position in CMMB in Q3 2021 and held it in 3 quarters. The position peaked at $2M in Q3 2021. 15 funds tracked by Wall St. Rank hold CMMB as of Q2 2022.

  • Cathie Wood reported no remaining Chemomab Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cathie Wood sold 198 Chemomab Therapeutics shares in Q2 2022, an estimated $4K.
  • Cathie Wood first reported a position in Chemomab Therapeutics in Q3 2021 and held it in 3 quarters.
  • Cathie Wood's Chemomab Therapeutics position peaked at $2M in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2022.

Based on ARK Investment Management's 13F filing for Q2 2022, filed 11 Jul 2022.